Dr Reddy’s reports higher sales but downturn in pretax profit

29 October 2014
drugs_pills_tablets_big

Indian generics drugmaker Dr Reddy’s Laboratories (NYSE: RDY) today reported its unaudited consolidated financial results for the quarter ended September 30, 2014, showing that revenues grew 7% to 35.88 billion rupees ($579 million).

Gross profit for the quarter rose 8% to 20.97 billion rupees, but pretax profit fell 10% to 6.94 billion rupees, or diluted earnings per share of 33.60 rupees, a drop of 17%. Dr Reddy’s shares dipped 1.1% to 3,046.35 rupees by late afternoon today.

Global generics

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics